Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 20/20 | 1.00 |
| ▸ | CDK4 | P11802 | 6/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 6/20 | 1.00 |
| ▸ | CCND1 | P24385 | 6/20 | 1.00 |
| ▸ | CDK2 | P24941 | 6/20 | 1.00 |
| ▸ | CCND3 | P30281 | 6/20 | 1.00 |
| ▸ | CDK1 | P06493 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5252274 | 1.00 | CHEK1 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5247485 | 0.96 | CHEK1 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5250381 | 0.94 | CHEK1 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5256521 | 0.92 | CHEK1 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL7232225 | 0.92 | CHEK1 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5251094 | 0.87 | CHEK1 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5253201 | 0.86 | CHEK1 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5248605 | 0.86 | CHEK1 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5254645 | 0.86 | CHEK1 (0.78) | CHEK1CDK4CCNA2CCND1CDK2 | |
| SCHEMBL5250748 | 0.86 | CHEK1 (1.00) | CHEK1CDK4CCNA2CCND1CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | KANIA ROBERT STEVEN (US) | 2004-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220248-A1 | INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING PROTEIN KINASES, AND METHODS FOR THEIR USE | CDK3, BRAF, ROCK1 | CHEK1 320/4885CDK4 10/4885CCNA2 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.